Literature DB >> 12621496

Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.

F Fagioli1, E Biasin, M Berger, F Nesi, E H Saroglia, R Miniero, S Martino, P A Tovo.   

Abstract

We describe the successful unrelated cord blood transplantation in two patients affected by a Zap-70 deficiency and an Omenn-like syndrome, respectively. The patients were hospitalised for recurrent infections at the age of 13 and 2 months, respectively. An unrelated cord blood unit was found for each. The conditioning regimen was cyclophosphamide, busulfan and antithymocyte globulin. The total number of infused cells was 15.1 x 10(7)/kg and 17 x 10(7)/kg, respectively. Neutrophil engraftment was achieved on days +15 and +23, and platelet count >50 x 10(9)/l was achieved on days +21 and +52, respectively. One patient presented acute Graft-versus-host disease (GVHD) grade I and the other grade III. Chimerism was mixed and full donor. Normal lymphoproliferative response to mitogens and alloantigens was detectable at 6 months for both. No chronic GVHD was observed in either. The patients are alive and well at 53 and 15 months after transplantation. In conclusion, umbilical cord blood represents a valid alternative source of haemopoietic stem cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621496     DOI: 10.1038/sj.bmt.1703800

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

Review 1.  ZAP70: a master regulator of adaptive immunity.

Authors:  Alain Fischer; Capucine Picard; Karine Chemin; Stéphanie Dogniaux; Françoise le Deist; Claire Hivroz
Journal:  Semin Immunopathol       Date:  2010-02-05       Impact factor: 9.623

2.  Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.

Authors:  Seok-Gu Kang; Chung Hun Ryu; Sin Soo Jeun; Chun Kun Park; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2004-02-13       Impact factor: 1.475

3.  Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for ZAP70 Deficiency.

Authors:  Geoffrey D E Cuvelier; Tamar S Rubin; Donna A Wall; Marlis L Schroeder
Journal:  J Clin Immunol       Date:  2016-07-20       Impact factor: 8.542

4.  Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.

Authors:  A Iguchi; N Kawamura; R Kobayashi; S-I Takezaki; Y Ohkura; J Inamoto; J Ohshima; M Ichikawa; T Sato; M Kaneda; Y Cho; M Yamada; I Kobayashi; T Ariga
Journal:  Bone Marrow Transplant       Date:  2011-01-24       Impact factor: 5.483

5.  Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.

Authors:  Niusha Sharifinejad; Mahnaz Jamee; Majid Zaki-Dizaji; Bernice Lo; Mohammadreza Shaghaghi; Hamed Mohammadi; Farhad Jadidi-Niaragh; Shiva Shaghaghi; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi; Gholamreza Azizi
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

Review 6.  Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives.

Authors:  Riccardo Castagnoli; Ottavia Maria Delmonte; Enrica Calzoni; Luigi Daniele Notarangelo
Journal:  Front Pediatr       Date:  2019-08-08       Impact factor: 3.418

Review 7.  Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair.

Authors:  Michaël Schreurs; C Maarten Suttorp; Henricus A M Mutsaers; Anne Marie Kuijpers-Jagtman; Johannes W Von den Hoff; Edwin M Ongkosuwito; Paola L Carvajal Monroy; Frank A D T G Wagener
Journal:  Med Res Rev       Date:  2019-05-18       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.